BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3708614)

  • 1. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.
    Cervantes F; Reverter JC; Montserrat E; Rozman C
    Cancer Treat Rep; 1986 May; 70(5):665-7. PubMed ID: 3708614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment with CEP (CCNU, VP-16 and prednimustine) in Hodgkin's disease resistant to CVPP and ABVD. Results in 21 patients].
    Cervantes F; Reverter JC; Bladé J; Montserrat E; Rozman C
    Sangre (Barc); 1988 Jun; 33(3):184-7. PubMed ID: 2459787
    [No Abstract]   [Full Text] [Related]  

  • 4. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-line salvage chemotherapy in Hodgkin's disease.
    Bonadonna G; Viviani S; Valagussa P; Bonfante V; Santoro A
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):23-5. PubMed ID: 2579440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.
    Tseng A; Jacobs C; Coleman CN; Horning SJ; Lewis BJ; Rosenberg SA
    Cancer Treat Rep; 1987 May; 71(5):475-8. PubMed ID: 3567972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of advanced stage Hodgkin disease with CCNU, etoposide and prednimustine (CEP)].
    Illés A; Bányai A; Szegedi G
    Orv Hetil; 1994 May; 135(22):1187-90. PubMed ID: 8015814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease.
    Koza I; Bohunický L; Mociková K; Gyárfás J; Svancárová L; Mardiak J; Spánik S; Fuchsberger P; Thalmeinerová Z; Sufliarsky J
    Neoplasma; 1991; 38(6):583-93. PubMed ID: 1722564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
    Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
    Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
    Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of resistant Hodgkin's disease with CCNU, etoposide and prednimustine (CEP).
    Szántó I; Fleischmann T; Eckhardt S
    Oncology; 1991; 48(6):456-8. PubMed ID: 1749581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
    Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
    J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third-line chemotherapy with CAVP (CCNU, melphalan, etoposide and prednisone) in refractory Hodgkin's disease.
    Cartoni C; Cimino G; Anselmo AP; Amadori S; Mandelli F
    Haematologica; 1989; 74(3):273-7. PubMed ID: 2511096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.